ğŸ‘ ç”¨äºè¯„ä¼°ç»“åˆäº²å’ŒåŠ›çš„MMPBSAå’ŒMMGBSAæ–¹æ³•ç»¼è¿°

---
[TOC]

---


## å‚è€ƒæ–‡çŒ®
1. Genheden S, Ryde U. The MM/PBSA and MM/GBSA methods to estimate Sligand-binding affinities[J]. Expert opinion on drug discovery, 2015, 10(5): 449-461. [æ–‡çŒ®pdf](./ç”¨äºè¯„ä¼°ç»“åˆäº²å’ŒåŠ›çš„MMPBSAå’ŒMMGBSAæ–¹æ³•ç»¼è¿°/iedc-10-449.pdf)

2. [MMPBSAå’ŒMMGBSAå¯¹è›‹ç™½é…ä½“è‡ªç”±èƒ½è®¡ç®—ç²¾åº¦çš„è¯„ä¼°ç ”ç©¶](./ç”¨äºè¯„ä¼°ç»“åˆäº²å’ŒåŠ›çš„MMPBSAå’ŒMMGBSAæ–¹æ³•ç»¼è¿°/MM_PBSAå’ŒMM_GB...ä½“è‡ªç”±èƒ½è®¡ç®—ç²¾åº¦çš„è¯„ä¼°ç ”ç©¶_ä¾¯å»·å†›.pdf)

3. [End-Point Binding Free Energy Calculation with MM/PBSA and MM/GBSA: Strategies and Applications in Drug Design](./ç”¨äºè¯„ä¼°ç»“åˆäº²å’ŒåŠ›çš„MMPBSAå’ŒMMGBSAæ–¹æ³•ç»¼è¿°/acs.chemrev.9b00055.pdf)